Calithera Biosciences Inc (NASDAQ:CALA) – Equities researchers at William Blair lifted their FY2019 earnings estimates for Calithera Biosciences in a research note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($1.97) per share for the year, up from their previous forecast of ($2.23). William Blair also issued estimates for Calithera Biosciences’ Q4 2019 earnings at ($0.40) EPS, Q1 2020 earnings at ($0.42) EPS, Q2 2020 earnings at ($0.45) EPS, Q3 2020 earnings at ($0.44) EPS, Q4 2020 earnings at ($0.46) EPS, FY2020 earnings at ($1.78) EPS, FY2021 earnings at ($1.80) EPS and FY2022 earnings at ($0.75) EPS.

CALA has been the topic of several other research reports. ValuEngine raised Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, November 11th. Citigroup set a $8.00 price target on Calithera Biosciences and gave the company a “hold” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research raised Calithera Biosciences from a “sell” rating to a “hold” rating in a research note on Monday.

Shares of Calithera Biosciences stock opened at $3.38 on Monday. Calithera Biosciences has a 52 week low of $2.45 and a 52 week high of $6.90. The business’s fifty day simple moving average is $2.96 and its 200-day simple moving average is $4.15. The firm has a market cap of $181.22 million, a PE ratio of -2.27 and a beta of 1.81. The company has a quick ratio of 8.06, a current ratio of 7.39 and a debt-to-equity ratio of 0.06.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.07.

Hedge funds have recently bought and sold shares of the stock. Beddow Capital Management Inc. purchased a new stake in shares of Calithera Biosciences in the 2nd quarter valued at $44,000. Wedbush Securities Inc. purchased a new stake in shares of Calithera Biosciences in the 3rd quarter valued at $42,000. Tower Research Capital LLC TRC purchased a new stake in shares of Calithera Biosciences in the 2nd quarter valued at $56,000. Panagora Asset Management Inc. purchased a new stake in shares of Calithera Biosciences in the 2nd quarter valued at $60,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Calithera Biosciences in the 2nd quarter valued at $63,000. Hedge funds and other institutional investors own 65.31% of the company’s stock.

In other Calithera Biosciences news, major shareholder Bvf Partners L. P/Il purchased 1,598,977 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were acquired at an average price of $2.60 per share, with a total value of $4,157,340.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Value Fund L. P. Biotechnology purchased 2,396,485 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $3.33 per share, for a total transaction of $7,980,295.05. In the last ninety days, insiders bought 4,123,950 shares of company stock worth $12,570,640. Corporate insiders own 17.20% of the company’s stock.

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: Stock Symbol

Earnings History and Estimates for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.